Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
4
Neutral
8
Bullish
2
Bearish
7
Neutral
8
Bullish
31
Bearish
3
Neutral
0
Bullish
29
Discovery themes featuring this stock
Apollo Hospitals Enterprise Ltd is a pan‑India integrated healthcare provider operating hospitals, diagnostics, primary care clinics, an omni‑channel pharmacy distribution network and a large digital healthcare platform, with a consolidated network that includes 76 hospitals, ~10,325 capacity beds and material subsidiaries Apollo HealthCo and AHLL delivering out‑of‑hospital care and retail diagnostics.
Q3 FY26 consolidated revenues grew 17% year‑on‑year to ₹64,774 million with EBITDA up 27% to ₹9,653 million and PAT up 35% to ₹5,023 million, driven by 14% healthcare services growth, 20% HealthCo revenue growth and AHLL diagnostics expansion; digital losses narrowed significantly and HealthCo cash profit doubled versus prior year.
Apollo is pursuing an aggressive capacity build and M&A agenda: a ~₹8,200 crore bed expansion pipeline to add ~4,444 beds over FY26–FY30, plus a composite scheme to spin and list the combined HealthCo/Keimed entity as NewCo, an initiative that reconfigures ownership and aims to unlock value through listing by Q4 FY27.
Digital and platform businesses are scaling: Apollo 24|7 reports ~46 million registered users and ~9.5 lakh daily active users, platform GMV grew ~28% in Q3 FY26, Apollo Pharmacy operates 7,113 stores, and Apollo is integrating AI, telehealth and insurance solutions to increase omni‑channel customer journeys and diagnostic/pharmacy penetration across India.
Healthcare Services
Hospital
1,20,632 Cr
Low Risk
62.1
58.7
2.4
12.7
8,624.20
6,680.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
8389.75 | 1,20,632 Cr | 62.13 | 12.74 | 0.24 | 20.48 | 17.27 | 9.02 | ||
1025.00 | 99,631 Cr | 69.07 | 9.27 | 0.20 | 13.42 | 12.97 | 8.37 | ||
968.10 | 73,148 Cr | 70.21 | 7.39 | 0.10 | 10.53 | 12.56 | 6.67 | ||
777.00 | 40,395 Cr | 104.07 | 9.56 | 0.38 | 8.48 | 10.10 | 5.27 | ||
1863.50 | 38,070 Cr | 47.26 | 8.39 | 0.24 | 17.76 | 11.42 | 6.46 | ||
1245.00 | 33,219 Cr | 59.70 | 8.39 | 0.00 | 14.05 | 15.26 | 9.38 | ||
778.15 | 31,137 Cr | 128.98 | 13.85 | 0.00 | 10.74 | 7.99 | 3.12 | ||
| Median: 7 Co. | — | 1025.00 | 40,395 Cr | 69.07 | 9.27 | 0.20 | 13.42 | 12.56 | 6.67 |
Apollo Hospitals Enterprise Ltd (APOLLOHOSP) is currently trading at 8,454.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Apollo Hospitals Enterprise Ltd is a pan‑India integrated healthcare provider operating hospitals, diagnostics, primary care clinics, an omni‑channel pharmacy distribution network and a large digital healthcare platform, with a consolidated network that includes 76 hospitals, ~10,325 capacity beds and material subsidiaries Apollo HealthCo and AHLL delivering out‑of‑hospital care and retail diagnostics. Q3 FY26 consolidated revenues grew 17% year‑on‑year to ₹64,774 million with EBITDA up 27% to ₹9,653 million and PAT up 35% to ₹5,023 million, driven by 14% healthcare services growth, 20% HealthCo revenue growth and AHLL diagnostics expansion; digital losses narrowed significantly and HealthCo cash profit doubled versus prior year. Apollo is pursuing an aggressive capacity build and M&A agenda: a ~₹8,200 crore bed expansion pipeline to add ~4,444 beds over FY26–FY30, plus a composite scheme to spin and list the combined HealthCo/Keimed entity as NewCo, an initiative that reconfigures ownership and aims to unlock value through listing by Q4 FY27. Digital and platform businesses are scaling: Apollo 24|7 reports ~46 million registered users and ~9.5 lakh daily active users, platform GMV grew ~28% in Q3 FY26, Apollo Pharmacy operates 7,113 stores, and Apollo is integrating AI, telehealth and insurance solutions to increase omni‑channel customer journeys and diagnostic/pharmacy penetration across India.
Over the past 52 weeks, Apollo Hospitals Enterprise Ltd has traded between a low of ₹6,680.00 and a high of ₹8,624.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Apollo Hospitals Enterprise Ltd has a market capitalization of approximately 1,20,631.73. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Apollo Hospitals Enterprise Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 62.13 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,20,631.73 Cr, Apollo Hospitals Enterprise Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Apollo Hospitals Enterprise Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Apollo Hospitals Enterprise Ltd is 62.13. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Apollo Hospitals said it plans to appoint Shobana Kamineni as executive chairperson of Apollo Healthtech, subject to shareholder approval, as part of a demerger and separate listing plan.
Apollo Hospitals management has said the demerger process is expected to conclude by Q4 FY27, when the standalone entity could be listed.
Apollo Hospitals has guided that the demerger and listing process is targeted for completion by Q4 FY27, corresponding to the Jan to Mar 2027 period.
The company’s MD said Apollo targets adding 1,600 beds over the next 14 months, with other disclosures also describing nearly 1,700 beds across specific upcoming projects.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Scheme of Arrangement
Apollo Hospitals disclosed additional information on its proposed composite scheme to form and list Apollo Healthtech, covering governance (board composition, nomination rights with 10% fall-away), proposed Executive Chair Shobana Kamineni, and an investor-funded Upside Agreement (Rasmeli, up to 9% payable on achieving ≥4x MOIC), all subject to shareholder/NCLT approvals.
Scheme of Arrangement
Apollo Hospitals disclosed additional information on the proposed composite scheme to carve out/list Apollo Healthtech, detailing board composition (6 independent directors), nomination rights with 10% fall‑away, proposed Executive Chair Shobana Kamineni, and an investor‑funded Upside Agreement (max 9% for ≥4x MOIC), all subject to NCLT and shareholder approvals (including public shareholder approval under Reg 26(6)).
